Most sold healthcare stocks in Q1 2026
See which Healthcare stocks institutional investors trimmed or exited the most in Q1 2026, measured as net reductions in reported share positions from Q4 2025 into Q1 2026. Notable reductions at the top of this list include SANOFI-ADR (SNY), CVS HEALTH CORP (CVS), GSK PLC-SPON ADR (GSK), BOSTON SCIENTIFIC CORP (BSX). These rankings are based on SEC 13F filings from the investors we track.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| SNY | SANOFI-ADR | -26,968,565 | -$1.32B | 0 | 3 | 1 | 0 | 4 |
| CVS | CVS HEALTH CORP | -12,422,856 | -$1.51B | 1 | 1 | 8 | 0 | 12 |
| GSK | GSK PLC-SPON ADR | -10,629,912 | -$156.10M | 0 | 2 | 6 | 0 | 8 |
| BSX | BOSTON SCIENTIFIC CORP | -10,557,188 | -$1.40B | 0 | 3 | 2 | 2 | 7 |
| ELAN | ELANCO ANIMAL HEALTH INC | -10,146,632 | -$139.96M | 0 | 0 | 2 | 0 | 2 |
| UNH | UNITEDHEALTH GROUP INC | -5,265,934 | -$2.60B | 2 | 8 | 10 | 5 | 20 |
| RLYB | RALLYBIO CORP | -5,030,469 | -$3.45M | 0 | 0 | 0 | 2 | 0 |
| BMY | BRISTOL-MYERS SQUIBB CO | -4,742,138 | -$95.23M | 0 | 2 | 8 | 1 | 10 |
| SGMO | SANGAMO THERAPEUTICS INC | -4,593,658 | -$2.59M | 0 | 0 | 1 | 0 | 1 |
| HLN | HALEON PLC-ADR | -4,524,294 | -$60.82M | 0 | 2 | 3 | 0 | 5 |
| ABT | ABBOTT LABORATORIES | -3,623,342 | -$555.84M | 0 | 4 | 4 | 1 | 10 |
| DVAX | DYNAVAX TECHNOLOGIES CORP | -3,337,533 | -$51.33M | 0 | 0 | 0 | 1 | 0 |
| VEEV | VEEVA SYSTEMS INC-CLASS A | -3,261,266 | -$757.70M | 0 | 3 | 1 | 4 | 4 |
| LAB | STANDARD BIOTOOLS INC | -3,066,665 | -$25.08M | 0 | 0 | 0 | 1 | 1 |
| APLT | APPLIED THERAPEUTICS INC | -2,706,156 | -$270.62K | 0 | 0 | 0 | 1 | 0 |
| GILD | GILEAD SCIENCES INC | -2,668,809 | $115.99M | 0 | 1 | 4 | 0 | 6 |
| CPRX | CATALYST PHARMACEUTICALS INC | -2,611,359 | -$56.12M | 1 | 0 | 2 | 0 | 3 |
| PACB | PACIFIC BIOSCIENCES OF CALIF | -2,489,589 | -$25.97M | 0 | 0 | 2 | 1 | 2 |
| AZN | ASTRAZENECA PLC-SPONS ADR | -2,409,351 | -$221.49M | 0 | 0 | 0 | 4 | 0 |
| AGL | AGILON HEALTH INC | -2,398,851 | -$1.65M | 0 | 0 | 0 | 2 | 0 |
| NVS | NOVARTIS AG-SPONSORED ADR | -2,259,960 | -$189.85M | 1 | 2 | 4 | 1 | 7 |
| BBIO | BRIDGEBIO PHARMA INC | -2,181,169 | -$194.16M | 1 | 1 | 1 | 1 | 3 |
| WRBY | WARBY PARKER INC-CLASS A | -2,163,932 | -$52.25M | 0 | 0 | 3 | 0 | 3 |
| ATOS | ATOSSA THERAPEUTICS INC | -2,062,838 | -$1.22M | 0 | 0 | 0 | 1 | 0 |
| NUVB | NUVATION BIO INC | -1,981,829 | -$26.47M | 1 | 0 | 1 | 0 | 3 |
| GUTS | FRACTYL HEALTH INC | -1,827,851 | -$4.08M | 0 | 0 | 1 | 0 | 1 |
| AKBA | AKEBIA THERAPEUTICS INC | -1,760,005 | -$3.24M | 0 | 0 | 1 | 0 | 1 |
| OCGN | OCUGEN INC | -1,700,400 | -$2.30M | 0 | 0 | 0 | 1 | 0 |
| DVA | DAVITA INC | -1,641,466 | $1.03B | 0 | 1 | 2 | 0 | 3 |
| INCY | INCYTE CORP | -1,632,217 | -$238.81M | 0 | 1 | 3 | 1 | 4 |
| EXAS | EXACT SCIENCES CORP | -1,620,089 | -$164.54M | 0 | 0 | 0 | 4 | 0 |
| BAX | BAXTER INTERNATIONAL INC | -1,572,687 | -$346.00M | 0 | 4 | 3 | 0 | 8 |
| TXG | 10X GENOMICS INC-CLASS A | -1,491,852 | $38.28M | 0 | 0 | 2 | 0 | 2 |
| BHC | BAUSCH HEALTH COS INC | -1,457,419 | -$12.64M | 0 | 2 | 0 | 2 | 2 |
| IQV | IQVIA HOLDINGS INC | -1,387,926 | -$349.56M | 0 | 1 | 3 | 3 | 4 |
| NTLA | INTELLIA THERAPEUTICS INC | -1,370,777 | $43.25M | 0 | 1 | 0 | 1 | 1 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | -1,351,831 | -$9.21M | 0 | 0 | 1 | 0 | 1 |
| HOLX | HOLOGIC INC | -1,348,461 | -$100.42M | 0 | 1 | 1 | 2 | 2 |
| ORIC | ORIC PHARMACEUTICALS INC | -1,320,882 | $15.35M | 0 | 0 | 1 | 1 | 1 |
| IBRX | IMMUNITYBIO INC | -1,233,810 | -$2.29M | 0 | 0 | 1 | 1 | 1 |
| TWST | TWIST BIOSCIENCE CORP | -1,192,725 | $62.76M | 1 | 0 | 1 | 0 | 2 |
| CLOV | CLOVER HEALTH INVESTMENTS CO | -1,089,600 | -$4.57M | 0 | 0 | 1 | 0 | 1 |
| BFLY | BUTTERFLY NETWORK INC | -1,083,635 | -$2.77M | 0 | 0 | 2 | 0 | 2 |
| HBIO | HARVARD BIOSCIENCE INC | -1,021,241 | -$683.01K | 0 | 0 | 0 | 1 | 0 |
| TALK | TALKSPACE INC | -1,016,846 | $1.49M | 0 | 1 | 1 | 0 | 2 |
| AIRS | AIRSCULPT TECHNOLOGIES INC | -1,005,464 | -$1.99M | 0 | 0 | 0 | 1 | 0 |
| NVST | ENVISTA HOLDINGS CORP | -1,003,934 | $34.53M | 0 | 3 | 3 | 0 | 6 |
| RPTX | REPARE THERAPEUTICS INC | -981,360 | -$2.55M | 0 | 0 | 0 | 1 | 0 |
| ABCL | ABCELLERA BIOLOGICS INC | -981,108 | -$3.25M | 0 | 0 | 1 | 1 | 1 |
| ZNTL | ZENTALIS PHARMACEUTICALS INC | -945,600 | $642.20K | 0 | 0 | 1 | 0 | 1 |
Frequently asked questions about Most sold healthcare stocks in Q1 2026
What are the most sold Healthcare stocks in Q1 2026?
The most sold healthcare stocks in Q1 2026 are those with the largest decrease in reported share counts across tracked institutional investors compared to Q4 2025, based on SEC 13F filings.
Which healthcare stocks did institutional investors trimmed or exited the most in Q1 2026?
Among the managers we track, net reductions were largest in companies such as SANOFI-ADR (SNY), CVS HEALTH CORP (CVS), GSK PLC-SPON ADR (GSK), based on aggregated 13F data.
How is institutional selling calculated?
Selling is calculated by summing the net decrease in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q4 2025).
Does this include all institutional owners?
These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.